Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors
Loading...
Identifiers
Publication date
Advisors
Tutors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers
Metrics
Export
Abstract
In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) play a key immunosuppressive role that limits the ability of the immune system to fight cancer. Toll-like receptors (TLRs) ligands, such as poly(I:C) or resiquimod (R848) are able to reprogram TAMs towards M1-like antitumor effector cells. The objective of our work has been to develop and evaluate polymeric nanocapsules (NCs) loaded with poly(I:C)+R848, to improve drug stability and systemic toxicity, and evaluate their targeting and therapeutic activity towards TAMs in the TME of solid tumors
Description
Bibliographic citation
Anfray, C., Fernández Varela, C., Ummarino, A., Maeda, A., Sironi, M., Gandoy, S., Brea, J., Loza, M. I., León, S., Calvo, A., Correa, J., Fernandez-Megia, E., Alonso, M. J., Allavena, P., Crecente-Campo, J., Torres Andón, F. (2024). Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors. "Frontiers in Immunology", vol. 14
Relation
Has part
Has version
Is based on
Is part of
Is referenced by
Is version of
Requires
Publisher version
https://doi.org/10.3389/fimmu.2023.1334800Sponsors
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the 2-INTRATARGET project (PCIN-2017-129/ AEI) funded by MINECO-PCIN-2017-129/AEI, under the frame of EuroNanoMed III; and by the 2^2-INTRATARGET project (A20/ 00028) funded by the ISCIII (Spain) and by the IMH (Italy) under the frame of the ERA NET EuroNanoMed GA N 723770 of the EU Horizon 2020 Research and Innovation Programme (MA, AC, PA). Financial support was also obtained from Xunta de Galicia (ED431C 2022/21, and Centro Singular de Investigación de Galicia accreditation 2019-2022, ED431G2019/03) and the European Union (European Regional Development Fund-ERDF). AC was supported by grants from ISCIII (PI22/01253) and Gobierno de Navarra Salud. AU is supported by a FIRC-AIRC fellowship for Italy. FTA was supported by a grant by “Fundación de la Asociación Española Contra el Cáncer”, an “Oportunious” program grant by Xunta de Galicia, and is currently supported by a Miguel Servet Grant from the Instituto de Salud Carlos III (ISCIII), CP22/00106 by AES 2022, co-funded by the European Union.SL was supported by a fellowship form Asociacion de Amigos Universidad de Navarra
Rights
Attribution 4.0 International